Bradycardia Risk with Latuda, Valdoxan, and Dayvigo
Latuda (lurasidone) can cause bradycardia, though it is uncommon; Valdoxan (agomelatine) and Dayvigo (lemborexant) do not have established associations with bradycardia based on available evidence.
Latuda (Lurasidone)
Bradycardia is a documented but rare adverse effect of lurasidone. The FDA label for Latuda lists bradycardia as a potential cardiovascular adverse reaction, particularly in the context of orthostatic hypotension 1. The mechanism appears related to α1-adrenergic receptor antagonism, which can produce associated cardiovascular effects including tachycardia and bradycardia 1.
Clinical Evidence
A case report documented sinus bradycardia (heart rate dropping to 48 beats/min) in a 46-year-old woman with bipolar disorder after adding lurasidone 80 mg/day to her existing regimen of lithium and valproate 2. The bradycardia resolved within 5 days of discontinuing lurasidone, with heart rate returning to 80 beats/min, demonstrating a clear temporal relationship 2.
Monitoring Recommendations
- Monitor heart rate after initial administration, particularly during the first few days of treatment 2
- Greatest risk occurs at treatment initiation and during dose escalation 1
- Higher risk patients include those with:
- Cardiovascular disease (heart failure, myocardial infarction, conduction abnormalities)
- Concurrent use of other medications affecting heart rate
- Dehydration or hypovolemia
- Elderly patients 1
Management Approach
If bradycardia develops with associated symptoms (dizziness, lightheadedness), decrease the lurasidone dose or discontinue the medication 3, 4. Consider drug interactions, as other medications (beta-blockers, calcium channel blockers, digoxin, antiarrhythmic drugs) can potentiate bradycardia and may need adjustment or discontinuation 3, 4.
Valdoxan (Agomelatine)
No evidence in the provided literature links agomelatine to bradycardia. Agomelatine is mentioned only in the context of sleep disorder treatment guidelines 5, without any cardiovascular adverse effects noted. The drug's mechanism as a melatonin receptor agonist does not typically affect cardiac conduction.
Dayvigo (Lemborexant)
No evidence in the provided literature associates lemborexant with bradycardia. As an orexin receptor antagonist used for insomnia, lemborexant does not have documented effects on cardiac conduction or heart rate based on the available evidence.
Important Clinical Caveats
Bradycardia from any antiarrhythmic or psychotropic medication is generally asymptomatic and requires no treatment unless accompanied by symptoms (dizziness, lightheadedness) or progresses to second- or third-degree heart block 6, 3. When symptomatic bradycardia occurs, the priority is identifying and managing reversible causes, including medication effects 7, 8.
For lurasidone specifically, the cardiovascular effects are generally less significant than with many other antipsychotics 9, but vigilance is warranted, particularly in vulnerable populations and during the initial treatment period 2.